Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
- Positive results from the second cohort of the Phase 1 trial of Decoy20 for solid tumors
- Approval of a key patent by the European Patent Office for the Company's platform technology
- Financial highlights for the fourth quarter and fiscal year ended December 31, 2023
- Increase in research and development expenses for both the three-month and twelve-month periods
- Increase in general and administrative expenses for the twelve-month period
- Decrease in cash and cash equivalents from 2022 to 2023
- Guidance that current cash will support ongoing operating activities through the third quarter of 2024
- Loss per share increased from $1.73 to $1.83 for the twelve-month period
- Net cash used in operating activities increased by $0.3 million for the twelve-month period
- Net cash used in investing activities was higher in 2022 compared to 2023
Insights
The recent announcement by Indaptus Therapeutics regarding the positive results from the second cohort of its Phase 1 trial of Decoy20 is a significant milestone in the development of their lead candidate. The ability of Decoy20 to induce a broad immune response in patients with solid tumors, as demonstrated in the initial findings, suggests potential as an innovative cancer therapy. The progression to a multi-dose cohort is a critical step in evaluating the safety and efficacy of the treatment, which could have substantial implications for the company's valuation if successful. The immune response involving over fifty cytokines and chemokines indicates a robust engagement with the body's natural defense mechanisms, which might translate into clinical benefits for patients.
Moreover, the approval of a key patent by the European Patent Office enhances Indaptus's intellectual property portfolio, potentially providing a competitive edge and avenues for licensing or partnerships. This patent approval is a strategic asset, as it can safeguard the company's technological advancements and can be a factor in attracting investment or collaboration opportunities.
From a financial perspective, Indaptus Therapeutics' reported increase in research and development expenses reflects their investment in the clinical trial and pipeline expansion. While this is a common trend among biotech firms in the development phase, it is crucial to monitor how these investments translate into clinical success and potential marketable products. The reported loss per share increase is also typical for companies in this stage, but investors will be looking for signs of a turnaround as the product advances through the clinical pipeline.
The company's cash position and runway, which is expected to last through the third quarter of 2024, is a vital indicator of its ability to sustain operations without the immediate need for additional financing. However, with a decrease in cash and cash equivalents year-over-year, there is an implied urgency for the company to secure further funding or reach significant milestones that could lead to partnership deals or additional investment.
In the context of the broader oncology market, the development of treatments like Decoy20 is part of an ongoing trend towards personalized and targeted therapies. The positive response observed in the Phase 1 trial positions Indaptus Therapeutics in a competitive market space. However, the market for cancer immunotherapies is becoming increasingly crowded and the company's long-term success will depend on differentiating Decoy20 from other treatments, both in terms of efficacy and cost-effectiveness.
It is also important to consider the potential market size for Decoy20, which will be influenced by the types of solid tumors it can effectively treat. The specificity and safety profile demonstrated in multi-dosing studies will be key factors in determining the treatment's commercial viability and potential to capture market share.
- Announced Positive Results from Second Cohort of Phase 1 Trial of Decoy20
- Initiating Multi-Dosing for patients with solid tumors
NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) today announced financial results for the fourth quarter and fiscal year ended December 31, 2023 and provided a corporate update.
Jeffrey Meckler, Chief Executive Officer of Indaptus, commented, “We are thrilled with the progress we made in 2023, which was capped off in November when we announced that our lead candidate, Decoy20, demonstrated a broad immune response in patients following a single dose in the first cohort of our ongoing phase 1 study. More recently, in March 2024, we announced positive results from our second cohort. In close consultation with an independent Safety Review Committee, we are now initiating a multi-dose cohort. Our objective in this next part of the Phase 1 trial is to determine the safety of Decoy20, with multiple doses administered to the same patient, which we believe could also potentially enhance anti-tumor activity across various tumor types. As we are encouraged by these initial findings and by the anti-cancer activity we observed from multi-dosing in our pre-clinical models, we look forward to continuing our efforts to demonstrate safety and efficacy. We remain prudent in managing our cash position and furthering our research in a cost effective and efficient manner.”
Key recent highlights:
- In March 2024, the Company announced positive results from its second cohort of its Phase 1 trial of Decoy20, where patients continued to exhibit a broad immune response. The results were reviewed by the Company and an independent Safety Review Committee and based on this review, it was recommended to proceed to the next part of the trial and enroll patients who will receive multiple doses of Decoy20.
- In January 2024, a key patent for the Company was approved by the European Patent Office which relates to the Company’s platform technology, covering a composition that can be used in the prevention or treatment of viral infections.
- In November 2023, the Company announced that Decoy20 demonstrated a broad immune response of more than fifty cytokines and chemokines in patients following a single dose in the first cohort of ongoing Phase 1 study. These data, as well as additional human patient data, was presented at the Society for Immunotherapy for Cancer Conference.
Financial Highlights for Fourth Quarter and Fiscal Year Ended December 31, 2023
Research and development expenses for the three-month period ended December 31, 2023, were
General and administrative expenses for the three-month periods ended December 31, 2023 and 2022, were
Loss per share for the twelve-month period ended December 31, 2023 was
As of December 31, 2023, the Company had cash and cash equivalents of
Net cash used in operating activities was
Net cash provided by investing activities was
There was no net cash provided by or used in financing activities for the twelve-month periods ended December 31, 2023 and 2022.
About Indaptus Therapeutics
Indaptus Therapeutics has evolved from more than a century of immunotherapy advances. The Company’s novel approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be administered safely intravenously (i.v.). Indaptus’ patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria producing a multiple Toll-like receptor (TLR), Nucleotide oligomerization domain (NOD)-like receptor (NLR) and Stimulator of interferon genes (STING) agonist Decoy platform. The product candidates are designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cells and pathways of innate and adaptive immunity. Decoy product candidates represent an antigen-agnostic technology that have produced single-agent activity against metastatic pancreatic and orthotopic colorectal carcinomas, single agent eradication of established antigen-expressing breast carcinoma, as well as combination-mediated eradication of established hepatocellular carcinomas, pancreatic and non-Hodgkin’s lymphomas in standard pre-clinical models, including syngeneic mouse tumors and human tumor xenografts. In pre-clinical studies tumor eradication was observed with Decoy product candidates in combination with anti-PD-1 checkpoint therapy, low-dose chemotherapy, a non-steroidal anti-inflammatory drug, or an approved, targeted antibody. Combination-based tumor eradication in pre-clinical models produced innate and adaptive immunological memory, involved activation of both innate and adaptive immune cells, and was associated with induction of innate and adaptive immune pathways in tumors after only one i.v. dose of Decoy product, with associated “cold” to “hot” tumor inflammation signature transition. IND-enabling, nonclinical toxicology studies demonstrated i.v. administration without sustained induction of hallmark biomarkers of cytokine release syndromes, possibly due to passive targeting to liver, spleen, and tumor, followed by rapid elimination of the product. Indaptus’ Decoy product candidates have also produced significant single agent activity against chronic hepatitis B virus (HBV) and chronic human immunodeficiency virus (HIV) infections in pre-clinical models.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act. These include statements regarding management’s expectations, beliefs and intentions regarding, among other things: our expectations and plans regarding our Phase 1 clinical trial of Decoy20, including the timing and design thereof; the anticipated effects of our product candidates, including Decoy20; the plans and objectives of management for future operations; our research and development activities and costs; the sufficiency of our cash and cash equivalents to fund our ongoing activities and our cash management strategy; and our assessment of financing options to support our corporate strategy. Forward-looking statements can be identified by the use of forward-looking words such as “believe”, “expect”, “intend”, “plan”, “may”, “should”, “could”, “might”, “seek”, “target”, “will”, “project”, “forecast”, “continue” or “anticipate” or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to the following: our limited operating history; conditions and events that raise substantial doubt regarding our ability to continue as going concern; the need for, and our ability to raise, additional capital given our lack of current cash flow; our clinical and preclinical development, which involves a lengthy and expensive process with an uncertain outcome; our incurrence of significant research and development expenses and other operating expenses, which may make it difficult for us to attain profitability; our pursuit of a limited number of research programs, product candidates and specific indications and failure to capitalize on product candidates or indications that may be more profitable or have a greater likelihood of success; our ability to obtain and maintain regulatory approval of any product candidate; the market acceptance of our product candidates; our reliance on third parties to conduct our preclinical studies and clinical trials and perform other tasks; our reliance on third parties for the manufacture of our product candidates during clinical development; our ability to successfully commercialize Decoy20 or any future product candidates; our ability to obtain or maintain coverage and adequate reimbursement for our products; the impact of legislation and healthcare reform measures on our ability to obtain marketing approval for and commercialize Decoy20 and any future product candidates; product candidates of our competitors that may be approved faster, marketed more effectively, and better tolerated than our product candidates; our ability to adequately protect our proprietary or licensed technology in the marketplace; the impact of, and costs of complying with healthcare laws and regulations, and our failure to comply with such laws and regulations; information technology system failures, cyberattacks or deficiencies in our cybersecurity; and unfavorable global economic conditions. These and other important factors discussed under the caption “Risk Factors” included in our most recent Annual Report on Form 10-K filed with the SEC on March 13, 2024, and our other filings with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release . All forward-looking statements speak only as of the date of this press release and are expressly qualified in their entirety by the cautionary statements included in this press release. We undertake no obligation to update or revise forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events, except as required by applicable law.
Contact: investors@indaptusrx.com
Investor Relations Contact:
CORE IR
Louie Toma
louie@coreir.com
Media Contact:
CORE IR
Jules Abraham
julesa@coreir.com
917-885-7378
| INDAPTUS THERAPEUTICS, INC. | ||||||||
| Consolidated Balance Sheets | ||||||||
| December 31, | ||||||||
| 2023 | 2022 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 13,362,053 | $ | 9,626,800 | ||||
| Marketable securities | - | 16,806,009 | ||||||
| Prepaid expenses and other current assets | 633,156 | 811,433 | ||||||
| Total current assets | 13,995,209 | 27,244,242 | ||||||
| Non-current assets: | ||||||||
| Property and equipment, net | 735 | 2,019 | ||||||
| Right-of-use asset | 173,206 | 79,294 | ||||||
| Other assets | 754,728 | 738,251 | ||||||
| Total non-current assets | 928,669 | 819,564 | ||||||
| Total assets | $ | 14,923,878 | $ | 28,063,806 | ||||
| Liabilities and stockholders’ equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable and other current liabilities | $ | 2,672,327 | $ | 3,352,847 | ||||
| Operating lease liability, current portion | 101,705 | 80,494 | ||||||
| Total current liabilities | 2,774,032 | 3,433,341 | ||||||
| Non-current liabilities: | ||||||||
| Operating lease liability, net of current portion | 73,348 | - | ||||||
| Total non-current liabilities | 73,348 | - | ||||||
| Total liabilities | 2,847,380 | 3,433,341 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders’ equity: | ||||||||
| Common stock: | 84,011 | 84,011 | ||||||
| Additional paid in capital | 57,409,643 | 54,443,705 | ||||||
| Accumulated deficit | (45,417,156 | ) | (29,993,685 | ) | ||||
| Accumulated other comprehensive income | - | 96,434 | ||||||
| Total stockholders’ equity | 12,076,498 | 24,630,465 | ||||||
| Total liabilities and stockholders’ equity | $ | 14,923,878 | $ | 28,063,806 | ||||
| Consolidated Statements of Operations and Comprehensive Loss | ||||||||
| For the year ended December 31, | ||||||||
| 2023 | 2022 | |||||||
| Operating expenses: | ||||||||
| Research and development | $ | 7,621,707 | $ | 6,324,657 | ||||
| General and administrative | 8,756,767 | 8,586,249 | ||||||
| Total operating expenses | 16,378,474 | 14,910,906 | ||||||
| Loss from operations | (16,378,474 | ) | (14,910,906 | ) | ||||
| Other income, net | 955,003 | 588,108 | ||||||
| Net loss | $ | (15,423,471 | ) | $ | (14,322,798 | ) | ||
| Net loss available to common stockholders per share of common stock, basic and diluted | $ | (1.83 | ) | $ | (1.73 | ) | ||
| Weighted average number of shares used in calculating net loss per share, basic and diluted | 8,401,047 | 8,262,119 | ||||||
| Net loss | $ | (15,423,471 | ) | $ | (14,322,798 | ) | ||
| Other comprehensive income: | ||||||||
| Reclassification adjustment for interest earned on marketable securities included in net loss | (430,993 | ) | (110,002 | ) | ||||
| Change in unrealized gain on marketable securities | 334,559 | 206,436 | ||||||
| Comprehensive loss | $ | (15,519,905 | ) | $ | (14,226,364 | ) | ||
| Consolidated Statements of Cash Flows | ||||||||
| For the year ended December 31, | ||||||||
| 2023 | 2022 | |||||||
| Cash flows from operating activities: | ||||||||
| Net loss | $ | (15,423,471 | ) | $ | (14,322,798 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation | 1,284 | 1,781 | ||||||
| Stock-based compensation | 2,965,938 | 2,957,249 | ||||||
| Realized gain on assets held for sale | - | (24,155 | ) | |||||
| Interest earned on marketable securities | (430,993 | ) | (110,002 | ) | ||||
| Changes in operating assets and liabilities: | ||||||||
| Prepaid expenses and other current assets | 161,800 | 295,220 | ||||||
| Accounts payable and other current liabilities | (680,520 | ) | (1,154,829 | ) | ||||
| Other assets | - | (721,774 | ) | |||||
| Operating lease right-of-use asset and liability, net | 647 | 961 | ||||||
| Net cash used in operating activities | (13,405,315 | ) | (13,078,347 | ) | ||||
| Cash flows from investing activities: | ||||||||
| Proceeds received for assets held for sale | - | 172,555 | ||||||
| Purchase of marketable securities | (6,859,432 | ) | (29,599,573 | ) | ||||
| Maturity of marketable securities | 24,000,000 | 13,000,000 | ||||||
| Net cash provided by (used in) investing activities | 17,140,568 | (16,427,018 | ) | |||||
| Net increase (decrease) in cash and cash equivalents | 3,735,253 | (29,505,365 | ) | |||||
| Cash and cash equivalents at beginning of year | 9,626,800 | 39,132,165 | ||||||
| Cash and cash equivalents at end of year | $ | 13,362,053 | $ | 9,626,800 | ||||
| Noncash investing and financing activities | ||||||||
| ASC 842 lease renewal option exercise | $ | 236,506 | $ | - | ||||
| Issuance of initial commitment shares | $ | - | $ | 1,425 | ||||
| Change in accumulated other comprehensive (loss) income | $ | (96,434 | ) | $ | 96,434 | |||
| Supplemental cash flow disclosures | ||||||||
| Cash paid for income taxes | $ | 1,600 | $ | 2,400 | ||||
FAQ
What positive results did Indaptus announce from the second cohort of the Phase 1 trial of Decoy20?
What key patent was approved by the European Patent Office for Indaptus?
What were the financial highlights for the fourth quarter and fiscal year ended December 31, 2023, for Indaptus?
What was the net cash used in operating activities for the twelve-month period ended December 31, 2023, compared to 2022?
What was the guidance provided by Indaptus regarding its current cash and cash equivalents?
